Abbott Lowers 2026 Profit Forecast After Exact Sciences Deal
Abbott lowered its annual profit outlook to reflect costs from its Exact Sciences deal. Strong medical device sales helped it beat first-quarter estimates.
ABBOTT LABORATORIES has lowered its full-year profit forecast for 2026, citing a financial impact from its $23 billion acquisition of cancer-screening specialist EXACT SCIENCES CORP. The healthcare company now expects adjusted profit per share to range between $5.38 and $5.58, down from its previous guidance of $5.55 to $5.80. This revision follows a 20-cent-per-share hit related to the deal, which contributed to a premarket share price decline of more than 4%.
Despite the forecast adjustment, the company reported that the acquisition strengthens its position in the high-growth cancer diagnostics market. Chief Executive Robert Ford noted that the integration adds a valuable high-growth business to the firm's existing portfolio.
